Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Venous Thrombosis I: Introduction01:30

Venous Thrombosis I: Introduction

Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Transient Ischemic Attack l: Introduction01:26

Transient Ischemic Attack l: Introduction

A transient ischemic attack (TIA) is a brief episode of neurological dysfunction caused by a temporary, focal reduction in cerebral blood flow. Although symptoms resemble those of an ischemic stroke, the interruption in perfusion is short-lived and does not cause permanent infarction. TIAs are clinically important because they often serve as early warning events for future stroke.Mechanisms of Transient Cerebral IschemiaTransient cerebral ischemia may arise through several mechanisms. One...
Disorders of Hemostasis01:24

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Diabetic Retinopathy01:27

Diabetic Retinopathy

DefinitionDiabetic retinopathy is a microvascular complication of diabetes affecting the retinal blood vessels.Risk FactorsDiabetic retinopathy is present in almost all individuals with type 1 diabetes and more than 60% of those with type 2 diabetes after two decades of disease.The risk increases with poor glycemic control, hypertension, dyslipidemia, smoking, pregnancy, and puberty.Although cataracts and glaucoma are also more frequent in people with diabetes, retinopathy remains the leading...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Identification of allele-specific KIV-2 repeats and impact on Lp(a) measurements for cardiovascular disease risk.

bioRxiv : the preprint server for biology·2023
Same author

Analyses of registry data of patients with anti-GBM and antineutrophil cytoplasmatic antibody-associated (ANCA) vasculitis treated with or without therapeutic apheresis.

Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis·2021
Same author

Analysis of extracorporeal photopheresis within the frame of the WAA register.

Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis·2021
Same author

European dermatology forum - updated guidelines on the use of extracorporeal photopheresis 2020 - part 1.

Journal of the European Academy of Dermatology and Venereology : JEADV·2020
Same author

European dermatology forum: Updated guidelines on the use of extracorporeal photopheresis 2020 - Part 2.

Journal of the European Academy of Dermatology and Venereology : JEADV·2020
Same author

Patient blood management during the COVID-19 pandemic: a narrative review.

Anaesthesia·2020
Same journal

Therapeutic plasma exchange in Alzheimer's disease: From clinical trial to real-world evidence.

Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis·2026
Same journal

Successful treatment of pure red cell aplasia with Orelabrutinib following major ABO-incompatible hematopoietic stem cell transplantation for acute myeloid leukemia: A case report.

Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis·2026
Same journal

Technological advances in selective plasma adsorption: The MTx.100 column and the emergence of subtractive precision medicine.

Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis·2026
Same journal

What's happening? Editorial comment: Insights on artificial intelligence, cell therapy and stem cell transplantation safety.

Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis·2026
Same journal

Red blood cell transfusion in elderly patients: Hemoglobin thresholds and clinical outcomes.

Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis·2026
Same journal

A personalized view on how artificial intelligence will change the future of multidirectional cell therapy: From design and engineering foundation to some healthcare applications.

Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis·2026
See all related articles

Related Experiment Video

Updated: May 29, 2026

Thrombus Profiling Assay: A Microfluidics-Based Platform for Comprehensively Characterizing Biomechanical Thrombogenesis
08:50

Thrombus Profiling Assay: A Microfluidics-Based Platform for Comprehensively Characterizing Biomechanical Thrombogenesis

Published on: January 9, 2026

Thrombotic microangiopathy.

M Mörtzell1, G Berlin, T Nilsson

  • 1Department of Public Health and Medicine, Umeå University, Umea, Sweden. monika.mortzell@vll.se

Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis
|September 3, 2011
PubMed
Summary
This summary is machine-generated.

Thrombotic microangiopathy (TMA) presents as a histopathological finding in various diseases like TTP and HUS. Diagnosis requires thorough history, family history, and analysis of ADAMTS 13 and its antibodies.

More Related Videos

Microvascular Embolism Mouse Model for In Vivo Two-photon Microscopy Using Fluorescent Polystyrene Microspheres
08:29

Microvascular Embolism Mouse Model for In Vivo Two-photon Microscopy Using Fluorescent Polystyrene Microspheres

Published on: November 21, 2025

Endothelialized Microfluidics for Studying Microvascular Interactions in Hematologic Diseases
11:08

Endothelialized Microfluidics for Studying Microvascular Interactions in Hematologic Diseases

Published on: June 22, 2012

Related Experiment Videos

Last Updated: May 29, 2026

Thrombus Profiling Assay: A Microfluidics-Based Platform for Comprehensively Characterizing Biomechanical Thrombogenesis
08:50

Thrombus Profiling Assay: A Microfluidics-Based Platform for Comprehensively Characterizing Biomechanical Thrombogenesis

Published on: January 9, 2026

Microvascular Embolism Mouse Model for In Vivo Two-photon Microscopy Using Fluorescent Polystyrene Microspheres
08:29

Microvascular Embolism Mouse Model for In Vivo Two-photon Microscopy Using Fluorescent Polystyrene Microspheres

Published on: November 21, 2025

Endothelialized Microfluidics for Studying Microvascular Interactions in Hematologic Diseases
11:08

Endothelialized Microfluidics for Studying Microvascular Interactions in Hematologic Diseases

Published on: June 22, 2012

Area of Science:

  • Hematology
  • Pathology

Background:

  • Thrombotic microangiopathy (TMA) is a critical histopathological finding.
  • It is observed in diverse conditions, notably thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS).
  • Numerous secondary causes of TMA can closely resemble TTP or HUS.

Purpose of the Study:

  • To provide a concise overview of thrombotic microangiopathy (TMA).
  • To highlight the diagnostic considerations for TMA, differentiating it from TTP and HUS.

Main Methods:

  • Review of existing literature on TMA.
  • Emphasis on clinical and pathological features.
  • Discussion of diagnostic tools, including ADAMTS 13 activity and antibody testing.

Main Results:

  • TMA is characterized by microangiopathic hemolytic anemia, thrombocytopenia, and organ damage.
  • Secondary causes of TMA are common and can mimic primary TMA syndromes.
  • ADAMTS 13 assessment is crucial for distinguishing TTP from other TMA etiologies.

Conclusions:

  • TMA results from a variety of etiologies and pathological processes, manifesting in diverse clinical scenarios.
  • A comprehensive patient history, including family history, is essential for accurate diagnosis.
  • ADAMTS 13 enzyme activity and antibody levels are key indicators for guiding therapeutic decisions in TMA.